Poly-autoimmunity in patients with myasthenia gravis: A single-center experience

References

• Goris, A., and A. Liston. 2012. The immunogenetic architecture of autoimmune disease. Cold Spring Harbor Perspect Biol 4: a007260
   Google Scholar
• Moroni, L., I. Bianchi, and A. Lleo. 2012. Geoepidemiology, gender and autoimmune disease. Autoimmun. Rev. 11: A386–392
   PubMed Web of Science ®Google Scholar
• Cooper, G. S., M. L. K. Bynum, and E. C. Somers. 2009. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J. Autoimmun. 33: 197–207
   PubMed Web of Science ®Google Scholar
• Sardu, C., E. Cocco, A. Mereu, et al. 2012. Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One 7: e32487
   PubMedGoogle Scholar
• Rojas-Villarraga, A., J. Amaya-Amaya, A. Rodriguez-Rodriguez, et al. 2012. Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis. 2012: 254319
   PubMedGoogle Scholar
• Meriggioli, M. N., and D. B. Sanders. 2012. Muscle antibodies in myasthenia gravis: beyond diagnosis? Expert Rev. Clin. Immunol. 8: 427–438
   Web of Science ®Google Scholar
• Verschuuren, J. J., M. G. Huijbers, J. J. Plomp, et al. 2013. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun. Rev. 12: 918–923
   PubMed Web of Science ®Google Scholar
• Bhinder, S., V. Majithia, and V. Harisdangkul. 2006. Myasthenia gravis and systemic lupus erythematosus: truly associated or coincidental-two case reports and review of the literature. Clin. Rheumatol. 25: 555–556
   PubMed Web of Science ®Google Scholar
• Winkler, D. T., P. Strnad, M. L. Meier, et al. 2007. Myasthenia gravis, paraneoplastic pemphigus and thymoma, a rare triade. J. Neurol. 254: 1601–1603
   PubMed Web of Science ®Google Scholar
• Christensen, P. B., T. S. Jensen, I. Tsiropoulos, et al. 1995. Associated autoimmune diseases in myasthenia gravis: a population-based study. Acta Neurol. Scand. 91: 192–195
   PubMed Web of Science ®Google Scholar
• Kanazawa, M., T. Shimohata, K. Tanaka, and M. Nishizawa. 2007. Clinical features of patients with myasthenia gravis associated with autoimmune diseases. Eur. J. Neurol. 14: 1403–1404
   PubMed Web of Science ®Google Scholar
• Toth, C., D. McDonald, J. Oger, and K. Brownell. 2006. Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease. Acta Neurol. Scand. 114: 124–132
   PubMed Web of Science ®Google Scholar
• Ramanujam, R., F. Piehl, R. Pirskanen, et al. 2011. Diagnosis of concomitant autoimmunity in myasthenia gravis – lack of association with IgA deficiency. J. Neuroimmunol. 236: 118–122
   PubMed Web of Science ®Google Scholar
• Klein, R., A. Marx, P. Ströbel, et al. 2013. Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum. Immunol. 74: 1184–1193
   PubMed Web of Science ®Google Scholar
• Chen, Y.-L., J.-H. Yeh, and H.-C. Chiu. 2013. Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan. Acta Neurol. Scand. 127: 170–174
   PubMed Web of Science ®Google Scholar
• Bhibhatbhan, A., G. Kline, A. Vincent, and C. Toth. 2007. Anti-MuSK myasthenia gravis presenting with Epstein–Barr virus-associated mononucleosis and immune-mediated diabetes mellitus. Muscle Nerve 36: 264–266
   PubMed Web of Science ®Google Scholar
• Díaz-Manera, J., R. Rojas-García, E. Gallardo, et al. 2007. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nat. Clin. Pract. Neurol. 3: 405–410
   PubMedGoogle Scholar
• Spengos, K., S. Vassilopoulou, Y. Christou, and P. Manta. 2008. Sarcoidosis in a case of MuSK-positive myasthenia gravis. Neuromuscul. Disord. 18: 890–891
   PubMed Web of Science ®Google Scholar
• Nakata, R., M. Motomura, T. Masuda, et al. 2013. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis. Eur. J. Neurol. 20: 1272–1276
   PubMed Web of Science ®Google Scholar
• Skeie, G. O., S. Apostolski, A. Evoli, et al. 2010. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 17: 893–902
   PubMed Web of Science ®Google Scholar
• Pearce, E. N., J. V. Hennessey, and M. T. McDermott. 2011. New American Thyroid Association and American Association of Clinical Endocrinologists guidelines for thyrotoxicosis and other forms of hyperthyroidism: significant progress for the clinician and a guide to future research. Thyroid 21: 573–576
   PubMed Web of Science ®Google Scholar
• Tozzoli, R., N. Bizzaro, E. Tonutti, et al. 2002. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am. J. Clin. Pathol. 117: 316–324
   PubMed Web of Science ®Google Scholar
• Jiao, Y., J. P. Fryer, V. A. Lennon, et al. 2013. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 81: 1197–1204
   PubMed Web of Science ®Google Scholar
• Meriggioli, M. N., and D. B. Sanders. 2009. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 8: 475–490
   PubMed Web of Science ®Google Scholar
• Compston, D. A., A. Vincent, J. Newsom-Davis, and J. R. Batchelor. 1980. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103: 579–601
   PubMed Web of Science ®Google Scholar
• Giraud, M., C. Vandiedonck, and H. J. Garchon. 2008. Genetic factors in autoimmune myasthenia gravis. Ann. N. Y. Acad. Sci. 1132: 180–189
   PubMed Web of Science ®Google Scholar
• Lauriola, L., F. Ranelletti, N. Maggiano, et al. 2005. Thymus changes in anti-MuSK positive and negative myasthenia gravis. Neurology 64: 536–538
   PubMed Web of Science ®Google Scholar
• Bartoccioni, E., F. Scuderi, A. Augugliaro, et al. 2009. HLA class II analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 72: 195–197
   PubMed Web of Science ®Google Scholar
• Price, P., C. Witt, R. Allcock, et al. 1999. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol. Rev. 167: 257–274
   PubMed Web of Science ®Google Scholar
• Ide, A., S. R. Babu, D. T. Robles, et al. 2005. “Extended” A1, B8, DR3 haplotype shows remarkable linkage disequilibrium but is similar to non-extended haplotypes in terms of diabetes risk. Diabetes 54: 1879–1883
   PubMed Web of Science ®Google Scholar
• Lazaros. G., A. Aggelis, D. Tsiachris, et al. 2011. Pericardial effusion in a young patient with newly diagnosed systemic lupus erythematosus and a mediastinal mass. Hellenic J. Cardiol. 52: 448–451
   PubMed Web of Science ®Google Scholar
• Desforges-Bullet, V., G. Petit-Aubert, C. Collet-Gaudillat, et al. 2011. Thymic hyperplasia and Graves' disease: a non-fortuitous association. Case report and review of literature. Ann Endocrinol. (Paris) 72: 304–309
   PubMed Web of Science ®Google Scholar
• Provenzano, C., R. Ricciardi, F. Scuderi, et al. 2012. PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data. Neuromuscul. Disord. 22: 131–138
   PubMed Web of Science ®Google Scholar
• Iyer, A., L. Elsone, R. Appleton, and A. Jacob. 2014. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 47: 154–161
   PubMed Web of Science ®Google Scholar
• Okumura, M., Y. Fujii, H. Shiono, et al. 2008. Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen. Thorac. Cardiovasc. Surg. 56: 143–150
   PubMedGoogle Scholar
• Scarpino, S., A. Di Napoli, A. Stoppacciaro, et al. 2007. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin. Exp. Immunol. 149: 504–512
   PubMed Web of Science ®Google Scholar
• Marx, A., N. Willcox, M. I. Leite, et al. 2010. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 43: 413–427
   PubMed Web of Science ®Google Scholar
• Marx, A., F. Pfister, B. Schalke, et al. 2013. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun. Rev. 12: 875–884
   PubMed Web of Science ®Google Scholar
• Irani, S. R., S. Alexander, P. Waters, et al. 2010. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 133: 2734–2748
   PubMed Web of Science ®Google Scholar
• Lancaster, E., M. G. Huijbers, V. Bar, et al. 2011. Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia. Ann. Neurol. 69: 303–311
   PubMed Web of Science ®Google Scholar
• Rubio-Agusti, I., F. Perez-Miralles, T. Sevilla, et al. 2011. Peripheral nerve hyperexcitability: a clinical study of 38 patients. Neurology 76: 172–178
   PubMed Web of Science ®Google Scholar
• Maniaol, A. H., A. Elsais, Å. R. Lorentzen, et al. 2012. Late-onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One 7: e36603
   PubMed Web of Science ®Google Scholar
• Testi, M., C. Terracciano, A. Guagnano, et al. 2012. Association of HLA-DQB*05:02 and DRB*16 alleles with late-onset, nonthymomatous, AChR-Ab-positive myasthenia gravis. Autoimmune Dis. 2012: 541760
   PubMedGoogle Scholar
• Niks, E. H., J. B. Kuks, B. O. Roep, et al. 2006. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 66: 1772–1774
   PubMed Web of Science ®Google Scholar
• Alahgholi-Hajibehzad, M., V. Yilmaz, Y. Gülsen-Parman, et al 2013. Association of HLA-DRB1*14, -DRB1*16 and -DQB1*05 with MuSK-myasthenia gravis in patients from Turkey. Hum. Immunol. 74: 1633–1635
   PubMed Web of Science ®Google Scholar
• Zonana, M. F., E. Reyes, and A. K. Weisman. 2002. Coexistence of four autoimmune diseases in one patient: the kaleidoscope of autoimmunity. J. Clin. Rheumatol. 8: 322–325
   PubMed Web of Science ®Google Scholar
• Omar, H. A., M. A. Alzahrani, A. A. Al Bshabshe, et al. 2010. Systemic lupus erythematosus after thymectomy for myasthenia gravis: a case report and review of the literature. Clin. Exp. Nephrol. 14: 272–276
   PubMed Web of Science ®Google Scholar
• Fleisher, J., M. Richie, R. Price, et al. 2013. Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis. JAMA Neurol. 70: 1311–1314
   PubMedGoogle Scholar
• Ramos-Casals, M., R. Perez-Alvarez, C. Diaz-Lagares, et al.; BIOGEAS Study Group. 2010. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun. Rev. 9: 188–193
   PubMed Web of Science ®Google Scholar
• Fee, D. B., and E. J. Kasarskis. 2009. Myasthenia gravis associated with etanercept therapy. Muscle Nerve 39: 866–870
   PubMed Web of Science ®Google Scholar
• Sawada, J., A. Asanome, H. Endo, et al. 2013. A case of myasthenia gravis following sarcoidosis and rheumathoid arthritis. Rinsho Shinkeigaku 53: 351–355
   PubMedGoogle Scholar
• Bruzzese, V., C. Marrese, P. Scolieri, et al. 2014. Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF alpha therapy? Int. J. Rheum. Dis. [Epub ahead of print]. doi: 10.1111/1756-185X.12340
   PubMed Web of Science ®Google Scholar
• Berrih-Aknin, S. 2014. Myasthenia gravis: paradox versus paradigm in autoimmunity. J. Autoimmun. 52C: 1–28
   Google Scholar